Tin tức & Cập nhật
Xem bài viết Niệu khoa
Xem
Chỉ hiển thị Multimedia

Final PROpel data confirm OS advantage with abiraterone plus olaparib
01 Mar 2023
bởiJairia Dela Cruz
The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.
01 Mar 2023

SRT plus GnRH agonist with acetate/prednisone, apalutamide improves prostate cancer survival
24 Feb 2023
bởiStephen Padilla
Postoperative salvage radiotherapy (SRT) plus 6 months of androgen deprivation therapy (ADT) with abiraterone acetate/prednisone (AAP) and apalutamide (Apa) results in better progression-free (PFS) and metastasis-free survival (MFS) among patients with prostate cancer, findings from FORMULA-509 have shown. However, the primary analysis did not reach the prespecified threshold for statistical significance.
24 Feb 2023






